151 related articles for article (PubMed ID: 10923075)
1. Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome.
Chang CC; Cleveland RP
Arch Pathol Lab Med; 2000 Aug; 124(8):1152-6. PubMed ID: 10923075
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes.
Moon HW; Huh JW; Lee M; Hong KS; Chung WS
Korean J Lab Med; 2010 Apr; 30(2):97-104. PubMed ID: 20445324
[TBL] [Abstract][Full Text] [Related]
3. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
[TBL] [Abstract][Full Text] [Related]
5. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.
Chung JW; Park CJ; Cha CH; Cho YU; Jang S; Chi HS; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
Ann Clin Lab Sci; 2012; 42(3):271-80. PubMed ID: 22964615
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry.
Huang M; Li J; Zhao G; Sui X; Zhao X; Xu H
Int J Lab Hematol; 2010 Jun; 32(3):275-81. PubMed ID: 19968721
[TBL] [Abstract][Full Text] [Related]
7. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome.
Ogata K; Nakamura K; Yokose N; Tamura H; Tachibana M; Taniguchi O; Iwakiri R; Hayashi T; Sakamaki H; Murai Y; Tohyama K; Tomoyasu S; Nonaka Y; Mori M; Dan K; Yoshida Y
Blood; 2002 Dec; 100(12):3887-96. PubMed ID: 12393641
[TBL] [Abstract][Full Text] [Related]
10. Surface marker abnormalities in myelodysplastic syndromes.
Elghetany MT
Haematologica; 1998 Dec; 83(12):1104-15. PubMed ID: 9949628
[TBL] [Abstract][Full Text] [Related]
11. Value of Quantitative assessment of Myeloid Nuclear Differentiation Antigen expression and other flow cytometric parameters in the diagnosis of Myelodysplastic syndrome.
Somasundaram V; Soni S; Chopra A; Rai S; Mahapatra M; Kumar R; Pati H
Int J Lab Hematol; 2016 Apr; 38(2):141-50. PubMed ID: 26822549
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.
Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Dworzak M; Hasle H; Locatelli F; De Moerloose B; Schmugge M; Mejstrikova E; Nováková M; Zecca M; Zwaan CM; Te Marvelde JG; Langerak AW; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH
Haematologica; 2015 Mar; 100(3):315-23. PubMed ID: 25425683
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
[TBL] [Abstract][Full Text] [Related]
16. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic clustering of myelodysplastic syndromes.
Maynadié M; Picard F; Husson B; Chatelain B; Cornet Y; Le Roux G; Campos L; Dromelet A; Lepelley P; Jouault H; Imbert M; Rosenwadj M; Vergé V; Bissières P; Raphaël M; Béné MC; Feuillard J;
Blood; 2002 Oct; 100(7):2349-56. PubMed ID: 12239142
[TBL] [Abstract][Full Text] [Related]
18. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
19. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
